Burney Co. Sells 315 Shares of Thermo Fisher Scientific (TMO)

Burney Co. trimmed its stake in Thermo Fisher Scientific (NYSE:TMO) by 11.6% in the first quarter, HoldingsChannel.com reports. The firm owned 2,407 shares of the medical research company’s stock after selling 315 shares during the period. Burney Co.’s holdings in Thermo Fisher Scientific were worth $497,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TMO. Atria Investments LLC increased its holdings in Thermo Fisher Scientific by 4.6% in the fourth quarter. Atria Investments LLC now owns 8,254 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 364 shares during the period. Bank of Montreal Can grew its holdings in Thermo Fisher Scientific by 16.3% during the 4th quarter. Bank of Montreal Can now owns 290,892 shares of the medical research company’s stock worth $55,235,000 after acquiring an additional 40,877 shares during the period. Creative Planning grew its holdings in Thermo Fisher Scientific by 12.7% during the 4th quarter. Creative Planning now owns 23,020 shares of the medical research company’s stock worth $4,371,000 after acquiring an additional 2,592 shares during the period. First National Trust Co grew its holdings in Thermo Fisher Scientific by 33.9% during the 4th quarter. First National Trust Co now owns 4,897 shares of the medical research company’s stock worth $930,000 after acquiring an additional 1,239 shares during the period. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in Thermo Fisher Scientific by 6.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 4,483 shares of the medical research company’s stock worth $851,000 after acquiring an additional 257 shares during the period. Institutional investors and hedge funds own 86.52% of the company’s stock.

In other news, Director William G. Parrett sold 1,000 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $211.43, for a total transaction of $211,430.00. Following the transaction, the director now owns 11,660 shares of the company’s stock, valued at approximately $2,465,273.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 43,500 shares of company stock worth $9,129,330 in the last three months. Insiders own 0.49% of the company’s stock.

A number of brokerages have weighed in on TMO. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday. Morgan Stanley increased their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Leerink Swann reiterated an “outperform” rating and set a $239.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. Barclays increased their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. One equities research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $222.21.

Thermo Fisher Scientific opened at $211.01 on Friday, MarketBeat Ratings reports. The stock has a market cap of $84.12 billion, a PE ratio of 22.23, a P/E/G ratio of 1.53 and a beta of 1.14. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Thermo Fisher Scientific has a 1 year low of $209.10 and a 1 year high of $211.31.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.08. The company had revenue of $5.85 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The business’s revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.08 EPS. sell-side analysts expect that Thermo Fisher Scientific will post 10.9 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply